Genmab A/S (CPH:GMAB)
1,690.00
-17.00 (-1.00%)
Apr 28, 2026, 4:59 PM CET
Genmab Revenue
In the year 2025, Genmab had annual revenue of $3.72B USD with 19.19% growth. Genmab had revenue of $1.06B in the quarter ending December 31, 2025, with 3.03% growth.
Revenue
$3.72B
Revenue Growth
+19.19%
P/S Ratio
4.38
Revenue / Employee
$1.25M
Employees
2,973
Market Cap
103.75B DKK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.72B | 599.00M | 19.19% |
| Dec 31, 2024 | 3.12B | 731.00M | 30.59% |
| Jan 1, 2024 | 2.39B | 305.95M | 14.68% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| ALK-Abelló | 6.31B |
| Demant | 22.97B |
| H. Lundbeck | 24.63B |
| Zealand Pharma | 9.21B |
| Ambu A/S | 6.09B |
| Bavarian Nordic | 6.24B |
Genmab News
- 11 days ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
- 14 days ago - Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln - Nasdaq
- 14 days ago - Major Shareholder Announcement - GlobeNewsWire
- 14 days ago - Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026 - Finanz Nachrichten
- 14 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 - GlobeNewsWire
- 14 days ago - Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026 - Wallstreet:Online
- 15 days ago - Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment - GuruFocus
- 15 days ago - Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer - Finanz Nachrichten